topic

372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager
Sarina Piha-Paul, Alexander Starodub, Raghad Karim, Michael Shafique, Gabriel Tinoco Suarez, Curtis Ruegg, Victoria Smith, Patrick Chun

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A226-A227; DOI: 10.1136/jitc-2020-SITC2020.0372
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2
John Powderly, Bradley Carthon, Marc Ernstoff, Anthony Olszanski, John Wrangle, Anthony Shields, Sarina Piha-Paul, Kelly Curtis, Ilda Bidollari, Yangchun Du, Lei Sun, Emily Putiri, Yan Wang, Heather Losey, Bruce Dezube, Bruce Dezube, Ulka Vaishampayan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A227; DOI: 10.1136/jitc-2020-SITC2020.0373
376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors
Shubham Pant, Amishi Shah, Pavlos Msaouel, Matthew Campbell, Shi-Ming Tu, Jianjun Gao, George Blumenschein, Frank Mott, Xiuning Le, Mehmet Altan, Funda Meric-Bernstam, Timothy Yap, Vivek Subbiah, Jordi Rodon, Axel Glasmacher, Imke Mulder, Michael Chisamore, Alexander Stevenson, Nizar Tannir

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A229; DOI: 10.1136/jitc-2020-SITC2020.0376
377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
Claire Galand, Vignesh Venkatraman, Marilyn Marques, James Strauss, Richard Carvajal, Min Lim, Benjamin Morin, Olga Ignatovich, Mark Findeis, Dennis Underwood, Marc Van Dijk, Irina Shapiro, Lernik Ohanjanian, Anna Wijatyk, Nicholas Wilson, Jennifer Buell, Dhan Chand, David Savitsky, Anthony Tolcher

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A229-A230; DOI: 10.1136/jitc-2020-SITC2020.0377
380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors
David Hong, Sandip Patel, Manish Patel, Kimberly Musni, Marlisa Anderson, Sarah Cooley, Bahram Valamehr, Wayne Chu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A231-A232; DOI: 10.1136/jitc-2020-SITC2020.0380
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
Maura Gillison, Roger Cohen, Przemyslaw Twardowski, Ammar Sukari, Melissa Johnson, Rudy Lackner, Thomas Davis, Arthur DeCillis, Richard Hernandez, Jessica Price, Kevin Mancini, Mara Shainheit, Jessica Flechtner, Mark Awad

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A237; DOI: 10.1136/jitc-2020-SITC2020.0390
396 Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side
James Welsh, Colette Shen, Jessica Frakes, Jiaxin Niu, Jared Weiss, Jimmy Caudell, Hu Yun, Hampartsoum Barsoumian, Juliette Thariat, Sylvie Bonvalot, Zsusanna Papaï, Maria Angelica Cortez, Ping Zhang, Katherine Jameson, Patricia Said, Sébastien Paris, Tanguy Seiwert

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A241; DOI: 10.1136/jitc-2020-SITC2020.0396
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
Steven O’Day, Anthony El khoueiry, Chethan Ramamurthy, Andrea Bullock, Irina Shapiro, Serina, Haiyong Han, Lernik Ohanjanian Namagerdi, Remigiusz Kaleta, Anna Wijatyk, Olivia Wijatyk, Waldo Ortuzar, Marek Ancukiewicz, Jennifer Buell, Dhan Chand, Michael Gordon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A242; DOI: 10.1136/jitc-2020-SITC2020.0398
400 CoupledCARTM technology for treating thyroid cancer
Xingchen Liu, Keshu Zhou, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu, Lei Xiao, Lei Xiao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A243-A244; DOI: 10.1136/jitc-2020-SITC2020.0400
403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors
Timothy Price, Sant Chawla, Gerald Falchook, Hans Prenen, Iwona Lugowska, Vivek Subbiah, Jose Monzon, Yuichi Ozawa, Tobias Arkenau, Caio Rocha Lima, Yasutoshi Kuboki, Tomohiro Nishina, Mun Hui, Erik Rasmussen, Hansen Wong, Saltanat Najmi, Nooshin Sadraei

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A245; DOI: 10.1136/jitc-2020-SITC2020.0403

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages